A Managed Access Agreement (MAA) is the mechanism the NHS uses to fund an expensive medicine before the long-term evidence is complete. Patients get access; the NHS pays a confidential net price; the manufacturer continues to collect real-world data; and at a defined end-point NICE reviews whether to convert the conditional approval into routine commissioning or to withdraw it.

The MAA machinery is invisible to most people until it isn't. A patient picking up a chronic medicine that their neighbour can't get on the NHS may have been put on an MAA. A pharmacist asked why a newly licensed drug is available for one indication but not another may be looking at an MAA scope boundary. This piece explains how MAAs work, where they sit in the UK funding landscape, and what they mean at the dispensary.

Why conditional funding exists

Traditional NICE cost-effectiveness analysis depends on long-term data: survival curves, quality-of-life measures, durability of response. For some medicines — especially cancer drugs and rare-disease therapies — that data is still maturing when the regulatory approval lands. Options at that point are:

• Reject routine funding and let patients wait until long-term data exists.
• Approve routine funding based on short-term evidence and accept the uncertainty.
• Approve conditional funding for a defined period, during which additional data is collected and the manufacturer and NHS share risk.

MAAs take the third option. They exist because the NHS values patient access and wants to keep the price disciplined without waiting years for perfect evidence.

The two main MAA structures

Cancer Drugs Fund (CDF) MAAs cover oncology medicines. NHS England funds the medicine through the CDF budget for a defined period (usually up to two years) while the manufacturer collects outcomes data through the Systemic Anti-Cancer Therapy (SACT) dataset. At the end, NICE revisits the guidance.

Innovative Medicines Fund (IMF) MAAs cover non-cancer medicines with similar evidence-uncertainty profiles, including many rare-disease therapies and some HST-approved advanced therapies. The structure mirrors the CDF.

A third category exists — stand-alone MAAs for specific HST-approved medicines — but the framework is the same.

Examples of MAA-funded medicines

Not every medicine stays on an MAA forever. The point of the agreement is to resolve the uncertainty. Several medicines have already transitioned from CDF-MAA to routine commissioning as the real-world data matured. Others have been withdrawn when outcomes did not justify continued funding at the agreed price.

How the funding actually moves

Confidentiality is a defining feature of MAAs. The list price of the medicine is public; the net price the NHS actually pays after commercial agreements is not. This allows the manufacturer to offer steep discounts in the UK without undermining list prices elsewhere in the world.

The practical upshot for dispensing pharmacists is that the prescription looks normal. The medicine is dispensed as any other NHS medicine. The financial flow — manufacturer rebate, NHS England budget reconciliation, data return — happens in the background.

What this means at the pharmacy counter

Three scenarios are worth knowing.

Scope mismatch. An MAA defines the specific indication and patient group for which conditional funding applies. A patient whose consultant prescribes outside that scope may find the medicine is not fundable, or is funded through a different route. If a prescription looks unusual for a named MAA-listed medicine, a call to the prescriber is appropriate.

Transition from MAA to routine funding. When a medicine moves off an MAA into routine NICE TA commissioning, eligibility criteria can change — sometimes narrowing to the sub-population where the evidence is strongest. Community pharmacists may see patients whose long-standing medicine is now funded on a different basis. The clinical team will have communicated this, but patients will still have questions at the counter.

Withdrawal. A medicine whose MAA period ends without converting to routine funding is withdrawn. Patients already on it are typically managed through transitional arrangements, but new starts will not be funded. Pharmacies dispensing a recently withdrawn MAA medicine should expect queries from patients and should signpost to the prescribing team.

Where MAAs sit alongside other access routes

The UK medicine-access landscape has a handful of overlapping routes. MAAs coexist with:

• Early Access to Medicines Scheme (EAMS) — pre-licence access for unmet-need conditions. Funded by the manufacturer, not the NHS.
• Named-patient / specials supply — bespoke supply of unlicensed or specials medicines.
• NHS England clinical commissioning policies — specific funded indications outside NICE.
• Individual Funding Requests (IFR) — case-by-case funding decisions where the patient falls outside routine policy.
• Clinical trials — where the investigational medicinal product is supplied as trial stock.

Patients often do not know which route their medicine comes through. Pharmacists do not need to know the granular detail of each case, but recognising the framework helps when answering "why is this on the NHS for me but not for my friend's condition".

Why MAAs matter for the sector

The MAA framework is part of what allows the UK to integrate expensive new therapies faster than its NHS budget would otherwise accommodate. Without MAAs, more medicines would be rejected outright at NICE or approved only with long delays. For the pharmacy workforce, MAAs mean a steady flow of new medicines arriving in hospital and specialist settings — with all the training, cold-chain, and clinical governance work that implies. The growing PharmSee vacancy count in NHS specialist and PCN roles (/app/jobs) partly reflects this.

Where to go for more

• PharmSee pharmacy workforce dashboard: /salary
• Live pharmacy jobs: /app/jobs
• Pharmacy locator: /app/pharmacies

Caveats

This guide describes the MAA framework as it operates in England. Wales, Scotland and Northern Ireland have their own funding and commissioning arrangements that can differ in detail; the broader principle of conditional access and real-world data collection applies in each. The list of MAA medicines changes regularly — NICE and NHS England publish the authoritative current list.

Sources

• NICE, Managed Access programme documentation and current MAA list.
• NHS England, Cancer Drugs Fund and Innovative Medicines Fund guidance.
• NHS England, Specialised Services commissioning framework.